Interferons in Colorectal Cancer Pathogenesis and Therapy
- PMID: 38962090
- PMCID: PMC11220628
- DOI: 10.54457/dr.202401005
Interferons in Colorectal Cancer Pathogenesis and Therapy
Abstract
As key modulators of the immune response, interferons play critical roles following infection and during the pathogenesis of cancer. The idea that these cytokines might be developed as new therapies emerged soon after their discovery. While enthusiasm for this approach to cancer therapy has waxed and waned over the ensuing decades, recent advances in cancer immunotherapy and our improved understanding of the tumor immune environment have led to a resurgence of interest in this unique class of biologic drug. Here, we review how interferons influence the growth of colorectal cancers (CRCs) and highlight new insights into how interferons and drugs that modulate interferon expression might be most effectively deployed in the clinic.
Keywords: Cancer; Colorectal; Interferons; P53; Therapy.
Conflict of interest statement
Conflicts of interest All authors declared that there are no conflicts of interest.
Figures


Similar articles
-
Tumor inherent interferons: Impact on immune reactivity and immunotherapy.Cytokine. 2019 Jun;118:42-47. doi: 10.1016/j.cyto.2018.04.006. Epub 2018 Apr 19. Cytokine. 2019. PMID: 29681426 Review.
-
Future directions in the therapy for large bowel cancer.Cancer. 1982 Dec 1;50(11 Suppl):2647-56. Cancer. 1982. PMID: 6182979
-
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].Strahlenther Onkol. 2004 Apr;180(4):187-93. doi: 10.1007/s00066-004-9119-x. Strahlenther Onkol. 2004. PMID: 15057428 Review. German.
-
Engineering interferons and interleukins for cancer immunotherapy.Adv Drug Deliv Rev. 2022 Mar;182:114112. doi: 10.1016/j.addr.2022.114112. Epub 2022 Jan 24. Adv Drug Deliv Rev. 2022. PMID: 35085624 Review.
-
Viral recognition and the antiviral interferon response.EMBO J. 2023 Jul 17;42(14):e112907. doi: 10.15252/embj.2022112907. Epub 2023 Jun 27. EMBO J. 2023. PMID: 37367474 Free PMC article. Review.
Cited by
-
Anticancer Plant Secondary Metabolites Evicting Linker Histone H1.2 from Chromatin Activate Type I Interferon Signaling.Int J Mol Sci. 2025 Jan 4;26(1):375. doi: 10.3390/ijms26010375. Int J Mol Sci. 2025. PMID: 39796235 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous